References

1. GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019, 18, 56–87.
2. James, S.L.; Lucchesi, L.R.; Bisignano, C.; Castle, C.D.; Dingels, Z.V.; Fox, J.T.; Hamilton, E.B.; Liu, Z.; McCracken, D.; Nixon, M.R.; et al. Morbidity and mortality from road injuries: Results from the Global Burden of Disease Study 2017. Inj. Prev. 2020, 26 (Suppl. 1), i46–i56.
3. Bogoslovsky, T.; Wilson, D.; Chen, Y.; Hanlon, D.; Gill, J.; Jeromin, A.; Song, L.; Moore, C.; Gong, Y.; Kenney, K.; et al. Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid β up to 90 Days after Traumatic Brain Injury. J. Neurotrauma. 2017, 34, 66–73.
4. Stocchetti, N.; Carbonara, M.; Citerio, G.; Ercole, A.; Skrifvars, M.B.; Smielewski, P.; Zoerle, T.; Menon, D.K. Severe traumatic brain injury: Targeted management in the intensive care unit. Lancet Neurol. 2017, 16, 452–464.
5. Khellaf, A.; Khan, D.Z.; Helmy, A. Recent advances in traumatic brain injury. J. Neurol. 2019, 266, 2878–2889.
6. Capizzi, A.; Woo, J.; Verduzco-Gutierrez, M. Traumatic Brain Injury: An Overview of Epidemiology, Pathophysiology, and Medical Management. Med. Clin. N. Am. 2020, 104, 213–238.
7. Vella, M.A.; Crandall, M.L.; Patel, M.B. Acute Management of Traumatic Brain Injury. Surg. Clin. N. Am. 2017, 97, 1015–1030.
8. Ng, S.Y.; Lee, A.Y.W. Traumatic Brain Injuries: Pathophysiology and Potential Therapeutic Targets. Front. Cell. Neurosci. 2019, 13, 528.
9. Stocker, R.A. Intensive Care in Traumatic Brain Injury Including Multi-Modal Monitoring and Neuroprotection. Med. Sci. 2019, 7, 37.
10. Hosomi, S.; Ohnishi, M.; Ogura, H.; Shimazu, T. Traumatic brain injury-related inflammatory projection: Beyond local inflammatory responses. Acute Med. Surg. 2020, 7, e520.
11. Jha, R.M.; Kochanek, P.M.; Simard, J.M. Pathophysiology and treatment of cerebral edema in traumatic brain injury. Neuropharmacology 2019, 145 Pt B, 230–246.
12. Jarrahi, A.; Braun, M.; Ahluwalia, M.; Gupta, R.V.; Wilson, M.; Munie, S.; Ahluwalia, P.; Vender, J.R.; Vale, F.L.; Dhandapani, K.M.; et al. Revisiting Traumatic Brain Injury: From Molecular Mechanisms to Therapeutic Interventions. Biomedicines 2020, 8, 389.
13. Chakraborty, S.; Skolnick, B.; Narayan, R.K. Neuroprotection Trials in Traumatic Brain Injury. Curr. Neurol. Neurosci. Rep. 2016, 16, 29.
14. Mallah, K.; Couch, C.; Borucki, D.M.; Toutonji, A.; Alshareef, M.; Tomlinson, S. Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go from Here? Front. Immunol. 2020, 11, 2021.
15. Sakai, S.; Shichita, T. Inflammation and neural repair after ischemic brain injury. Neurochem. Int. 2019, 130, 104316.
16. Crupi, R.; Cordaro, M.; Cuzzocrea, S.; Impellizzeri, D. Management of Traumatic Brain Injury: From Present to Future. Antioxidants 2020, 9, 297.
17. Boismare, F. Souffrance cérébrale: Comportement et neurotransmetteurs sur des modeles expérimentaux. In Symposium Internacional Souffrance Cérébrale et Précurseurs des Phospholipides; Laboratoires Cassenne-Takeda: Paris, France, 1980.
18. Cohadon, F.; Rigoulet, M.; Averet, M.; Arrigoni, E. Membrane damage in acute brain trauma. Nouv. Presse Med. 1989, 10, 147–155.
19. Cohadon, F.; Rigoulet, M.; Guérin, B.; Vandendriessche, M. L’activité membranaire dans la souffrance cérébrale. Altérations des ATPases membranaires dans l’edème cérébral vasogénique. Restauration par un précurseur des phospholipides. In Symposium Internacional Souffrance Cérébrale et Précurseurs des Phospholipides; Laboratoires Cassenne-Takeda: Paris, France, 1980.
20. Cohadon, F. Physiopathologie des edèmes cérébraux. Rev. Neurol. 1987, 143, 3–20.
21. Rigoulet, M.; Guérin, B.; Cohadon, F.; Vandendriessche, M. Unilateral brain injury in the rabbit; reversible and irreversible damage of the membranal ATPases. J. Neurochem. 1979, 32, 535–541.
22. Secades, J.J.; Lozano, R. Traumatismos Craneoencefálicos: Revisión Fisiopatológica y Terapéutica. Aportaciones de la Citicolina; Excerpta Medica: Amsterdam, The Netherlands, 1991.
23. Homayoun, P.; Parkins, N.E.; Soblosky, J.; Carey, M.E.; Rodriguez de Turco, E.B.; Bazan, N.G. Cortical impact injury in rats promotes a rapid and sustained increase in polyunsaturated free fatty acids and diacylglycerols. Neurochem. Res. 2000, 25, 269–276.
24. Alberghina, M.; Giuffrida, A.M. Effect of hypoxia on the incorporation of [2-3H] glycerol and [1-14C]-palmitate into lipids of various brain regions. J. Neurosci. Res. 1981, 6, 403–419.
25. Goldberg, W.J.; Dorman, R.V.; Horrocks, L.A. Effects of ischemia and diglycerides on ethanolamine and choline phosphotransferase activities from rat brain. Neurochem. Pathol. 1983, 1, 225–234.
26. Goldberg, W.J.; Dorman, R.V.; Dabrowiecki, Z.; Horrocks, L.A. The effects of ischemia and CDPamines on Na+,K+-ATPase and acetylcholinesterase activities in rat brain. Neurochem. Pathol. 1985, 3, 237–248.
27. Han, M.; Sun, T.; Chen, H.; Han, M.; Wang, D. Potential sphingosine-1-phosphate-related therapeutic targets in the treatment of cerebral ischemia reperfusion injury. Life Sci. 2020, 249, 117542.
28. Solovieva, E.Y.; Farrahova, K.I.; Karneev, A.N.; Chipova, D.T. Phospholipids metabolism disorders in acute stroke. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova. 2016, 116, 104–112.
29. Wang, X.; Zhang, L.; Sun, W.; Pei, L.L.; Tian, M.; Liang, J.; Liu, X.; Zhang, R.; Fang, H.; Wu, J.; et al. Changes of Metabolites in Acute Ischemic Stroke and Its Subtypes. Front. Neurosci. 2021, 14, 580929.
30. Bazan, N.G. Docosanoids and elovanoids from omega-3 fatty acids are pro-homeostatic modulators of inflammatory responses, cell damage and neuroprotection. Mol. Aspects Med. 2018, 64, 18–33.
31. Tayebati, S.K.; Marucci, G.; Santinelli, C.; Buccioni, M.; Amenta, F. Choline-Containing Phospholipids: Structure-Activity Relationships Versus Therapeutic Applications. Curr. Med. Chem. 2015, 22, 4328–4340.
32. Chomova, M.; Zitnanova, I. Look into brain energy crisis and membrane pathophysiology in ischemia and reperfusion. Stress 2016, 19, 341–348.
33. Zhao, Y.Y.; Miao, H.; Cheng, X.L.; Wei, F. Lipidomics: Novel insight into the biochemical mechanism of lipid metabolism and dysregulation-associated disease. Chem. Biol. Interact. 2015, 240, 220–238.
34. Bogie, J.F.J.; Haidar, M.; Kooij, G.; Hendriks, J.J.A. Fatty acid metabolism in the progression and resolution of CNS disorders. Adv. Drug Deliv. Rev. 2020, 159, 198–213.
35. Espinós, C.; Galindo, M.I.; García-Gimeno, M.A.; Ibáñez-Cabellos, J.S.; Martínez-Rubio, D.; Millán, J.M.; Rodrigo, R.; Sanz, P.; Seco-Cervera, M.; Sevilla, T.; et al. Oxidative Stress, a Crossroad between Rare Diseases and Neurodegeneration. Antioxidants 2020, 9, 313.
36. Mizuma, A.; Yenari, M.A. Clinical perspectives on ischemic stroke. Exp. Neurol. 2021, 338, 113599.
37. Zweifler, R.M. Membrane stabilizer: Citicoline. Curr. Med. Res. Opin. 2002, 18 (Suppl. 2), S14–S17.
38. Poddar, J.; Pradhan, M.; Ganguly, G.; Chakrabarti, S. Biochemical deficits and cognitive decline in brain aging: Intervention by dietary supplements. J. Chem. Neuroanat. 2019, 95, 70–80.
39. Linnerbauer, M.; Rothhammer, V. Protective Functions of Reactive Astrocytes Following Central Nervous System Insult. Front. Immunol. 2020, 11, 573256.
40. Saver, J.L. Targeting the brain: Neuroprotection and neurorestoration in ischemic stroke. Pharmacotherapy 2010, 30, 62S–69S.
41. Jasielski, P.; Piędel, F.; Piwek, M.; Rocka, A.; Petit, V.; Rejdak, K. Application of Citicoline in Neurological Disorders: A Systematic Review. Nutrients 2020, 12, 3113.
42. Horrocks, L.A.; Dorman, R.V. Prevention by CDP-choline and CDPethanolamine of lipid changes during brain ischemia. In Novel Biochemical, Pharmacological and Clinical Aspects of Cytidinediphosphocholine; Zappia, V., Kennedy, E.P., Nilsson, B.I., Galletti, P., Eds.; Elsevier Science Publishing: Amsterdam, The Netherlands, 1985; pp. 205–215.
43. Le Poncin-Lafitte, M.; Dutertem, D.; Lageron, A.; Rapin, J.R. CDP-choline et accident cérébral expérimental d’origine vasculaire. Agressologie 1986, 27, 413–416.
44. Mykita, S.; Golly, F.; Dreyfus, H.; Freysz, L.; Massarelli, R. Effect of CDP-choline on hypocapnic neurons in culture. J. Neurochem. 1986, 47, 223–231.
45. Yasuhara, M.; Naito, H. Characteristic actions of CDP-choline on the central nervous system. Curr. Ther. Res. Clin. Exp. 1974, 16, 346–374.
46. Yasuhara, M.; Naito, H.; Tachibana, Y.; Yasuhara, A. An electrophysiological study on the effects of CDP-choline in the central nervous system. In Novel Biochemical, Pharmacological and Clinical Aspects of Cytidinediphosphocholine; Zappia, V., Kennedy, E.P., Nilsson, B.I., Galletti, P., Eds.; Elsevier Science Publishing: Amsterdam, The Netherlands, 1985; pp. 259–274.
47. Martí-Viaño, J.L.; Selles, J.; Orts, A.; Marco, J.; Vega, F.; Espluges, J. Antagonismo del coma barbitúrico mediante productos alertizantes. Estudio experimental. Rev. Esp. Anest. Reanim. 1978, 25, 21–28.
48. Ogashiwa, M.; Sano, K.; Manaka, S.; Kitamura, K.; Kagawa, M.; Takeuchi, K. Effectiveness of CDP-choline on disturbance of consciousness (DOC): 1. An experimental study of concussive head injury in mice. 2. A controlled trial in patients with DOC. In Novel Biochemical, Pharmacological and Clinical Aspects of Cytidinediphosphocholine; Zappia, V., Kennedy, E.P., Nilsson, B.I., Galletti, P., Eds.; Elsevier Science Publishing: Amsterdam, The Netherlands, 1985; pp. 317–327.
49. Watanabe, S.; Kono, S.; Nakashima, Y.; Mitsunobu, K.; Otsuki, S. Effects of various cerebral metabolic activators on glucose metabolism of brain. Folia Psychiat. Neurol. Jpn. 1975, 29, 67–76.
50. Alberghina, M.; Giuffrida-Stella, A.M. Changes of phospholipid metabolizing and lysosomal enzymes in hypoglossal nucleus and ventral horn motoneurons during regeneration of craniospinal nerves. J. Neurochem. 1988, 51, 15–20.
51. Arrigoni, E.; Averet, N.; Cohadon, F. Effects of CDP-choline on phospholipase A2 and cholinephosphotransferase activities following a cryogenic brain injury in the rabbit. Biochem. Pharmacol. 1987, 36, 3697–3700.
52. Freysz, L.; Golly, F.; Mykita, S.; Avola, R.; Dreyfus, H.; Massarelli, R. Metabolism of neuronal cell culture: Modifications induced by CDP-choline. In Novel Biochemical, Pharmacological and Clinical Aspects of Cytidinediphosphocholine; Zappia, V., Kennedy, E.P., Nilsson, B.I., Galletti, P., Eds.; Elsevier Science Publishing: Amsterdam, The Netherlands, 1985; pp. 117–125.
53. Massarelli, R.; Mozzi, R.; Golly, F.; Hattori, H.; Dainous, F.; Kanfer, J.N.; Freysz, L. Synthesis de novo of choline, production of choline from phospholipids, and effects of CDP-choline on nerve cell survival. Fidia Res. Ser. 1986, 4, 273–281.
54. Kitazaki, T.; Ohta, Y.; Tsuda, M. Inhibition of membrane associated phospholipase A2 by CDP-choline. Jpn. Pharmacol. Ther. 1985, 13, 159–164.
55. Farooqui, A.A.; Litsky, M.L.; Farooqui, T.; Horrocks, L.A.. Inhibitors of intracellular phospholipase A2 activity: Their neurochemical effects and therapeutical importance for neurological disorders. Brain Res. Bull. 1999, 49, 139–153.
56. Algate, D.R.; Beard, D.J.; Sacristán, A.; Ortíz, J.A.; Davies, J.E. Study on the effects of oral administration of CDP-choline on EEG changes and lethality induced by epidural compression in the anesthetised cat. Arzneimittelforschung 1983, 33, 1013–1016.
57. Hayaishi, O.; Ozawa, K.; Araki, C.; Ishii, S.; Kondo, Y. Biochemical studies of head injury and brain edema. Jpn. J. Med. Prog. 1961, 48, 519–539.
58. Kondo, Y. Experimental study of the therapeutic use of cytidine nucleotids for brain injury. Nihon Geka Hokan. 1968, 32, 489–505.
59. Tsuchida, T.; Nagai, M.; Hoshino, T.; Kamano, S.; Miyake, H. Treatment of head injuries with intermediate substances of metabolic cycle of brain. II. Basic study on metabolism of cytidine diphosphate choline. Brain Nerve 1967, 19, 1041–1045.
60. Boismare, F.; Le Poncin, M.; Le François, J.; Hacpille, L.; Marchand, J.C. Étude des effets de l’administration de cytidinediphosphocholine sur les consèquences hémodynamiques, fonctionelles et biochimiques du traumatisme crâniocervical chez le rat. Thérapie 1977, 32, 345–354.
61. Clendenon, N.R.; Palayoor, S.T.; Gordon, W.A. Influence of CDP-choline on ATPase activity in acute experimental spinal cord trauma. In Novel Biochemical, Pharmacological and Clinical Aspects of Cytidinediphosphocholine; Zappia, V., Kennedy, E.P., Nilsson, B.I., Galletti, P., Eds.; Elsevier Science Publishing: Amsterdam, The Netherlands, 1985; pp. 275–284.
62. Cohadon, F.; Rigoulet, M.; Guérin, B.; Vandendriessche, M. Edème cérébral vasogénique. Altérations des ATPases membranaires. Restauration par un précurseur des phospholipides. Nouv. Presse Med. 1979, 8, 1589–1591.
63. Lafuente, J.V.; Cervós-Navarro, J. Estudio por microgavimetría del efecto de la CDP-colina en el edema cerebral experimental inducido por radiaciones ultravioletas. Med. Clin. 1986, 87 (Suppl. 1), 5–8.
64. Cervós-Navarro, J.; Lafuente, J.V. Effect of cytidine diphosphate choline on ultraviolet-induced brain edema. Adv. Neurol. 1990, 52, 421–429.
65. Majem, X.; Bidón-Chanal, A.; Vilá-Badó, J. Estudio de los efectos del tratamiento oral con CDP-colina sobre los cambios inducidos por el edema encefálico experimental en el electroencefalograma de la rata no anestesiada. Med. Clin. 1986, 87 (Suppl. 1), 23–25.
66. Roda, J.E. Répartition macro et microscopique d’un oedème cérébral vasogenique experimental. In Symposium International: Souffrance Cérébrale et Précurseurs des Phospholipides; Laboratoires Cassenne-Takeda: Paris, France, 1980.
67. Schmidt, K.; Hernekamp, J.F.; Doerr, M.; Zivkovic, A.R.; Brenner, T.; Walther, A.; Weigand, M.A.; Hofer, S. Cytidine-5-diphosphocholine reduces microvascular permeability during experimental endotoxemia. BMC Anesthesiol. 2015, 15, 114.
68. Hernekamp, J.F.; Hu, S.X.; Schmidt, V.J.; Vogelpohl, J.; Kneser, U.; Kremer, T. Influence of Cdp-Choline Administration on Early Burn Edema in Rats. Ann. Plast. Surg. 2015, 75, 388–392.
69. Dixon, C.E.; Ma, X.; Marion, D.W. Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. J. Neurotrauma 1997, 14, 161–169.
70. Plataras, C.; Tsakiris, S.; Angelogianni, P. Effect of CDP-choline on brain acetylcholinesterase and Na(+), K(+)-ATPase in adult rats. Clin. Biochem. 2000, 33, 351–357.
71. Başkaya, M.K.; Doğan, A.; Rao, A.M.; Dempsey, R.J. Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. J. Neurosurg. 2000, 92, 448–452.
72. Dempsey, R.J.; Raghavendra Rao, V.L. Cytidinediphosphocholine treatment to decrease traumatic brain injury-induced hippocampal neuronal death, cortical contusion volume, and neurological dysfunction in rats. J. Neurosurg. 2003, 98, 867–873.
73. Menku, A.; Ogden, M.; Saraymen, R. The protective effects of propofol and citicoline combination in experimental head injury in rats. Turk Neurosurg. 2010, 20, 57–62.
74. Jacotte-Simancas, A.; Costa-Miserachs, D.; Coll-Andreu, M.; Torras-Garcia, M.; Borlongan, C.V.; Portell-Cortés, I. Effects of voluntary physical exercise, citicoline, and combined treatment on object recognition memory, neurogenesis, and neuroprotection after traumatic brain injury in rats. J. Neurotrauma 2015, 32, 739–751.
75. Qian, K.; Gu, Y.; Zhao, Y.; Li, Z.; Sun, M. Citicoline protects brain against closed head injury in rats through suppressing oxidative stress and calpain over-activation. Neurochem. Res. 2014, 39, 1206–1218.
76. Gan, D.; Wu, S.; Chen, B.; Zhang, J. Application of the Zebrafish Traumatic Brain Injury Model in Assessing Cerebral Inflammation. Zebrafish 2020, 17, 73–82.
77. Cakir, E.; Usul, H.; Peksoylu, B.; Sayin, O.C.; Alver, A.; Topbas, M.; Baykal, S.; Kuzeyli, K. Effects of citicoline on experimental spinal cord injury. J. Clin. Neurosci. 2005, 12, 923–926.
78. Yücel, N.; Cayli, S.R.; Ateş, O.; Karadağ, N.; Firat, S.; Turköz, Y. Evaluation of the neuroprotective effects of citicoline after experimental spinal cord injury: Improved behavioral and neuroanatomical recovery. Neurochem. Res. 2006, 31, 767–775.
79. Coskun, C.; Avci, B.; Ocak, N.; Yalcin, M.; Dirican, M.; Savci, V. Effect of repeatedly given CDP-choline on cardiovascular and tissue injury in spinal shock conditions: Investigation of the acute phase. J. Pharm. Pharmacol. 2010, 62, 497–506.
80. Turkkan, A.; Alkan, T.; Goren, B.; Kocaeli, H.; Akar, E.; Korfali, E. Citicoline and postconditioning provides neuroprotection in a rat model of ischemic spinal cord injury. Acta Neurochir. 2010, 152, 1033–1042.
81. Galletti, P.; De Rosa, M.; Cotticelli, M.G.; Morana, A.; Vaccaro, R.; Zappia, V. Biochemical rationale for the use of CDPcholine in traumatic brain injury: Pharmacokinetics of the orally administered drug. J. Neurol. Sci. 1991, 103, S19–S25.
82. Qureshi, I.; Endres, J.R. Citicoline: A novel therapeutic agent with neuroprotective, neuromodulatory, and neuroregenerative properties. Nat. Med. J. 2010, 2, 11–25.
83. Saver, J.L. Target brain: Neuroprotection and neurorestoration in ischemic stroke. Rev. Neurol. Dis. 2010, 7 (Suppl. 1), s14–s21.
84. Secades, J.J. Citicoline: Pharmacological and clinical review, 2016 update. Rev. Neurol. 2016, 63, S1–S73.
85. Alvarez-Sabín, J.; Román, G.C. The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sci. 2013, 3, 1395–1414.
86. Moriyama, M.; Tsukumo, T.; Nakagawa, Y. Effects of CDPcholine on head injury. Gendai No Rinsho 1967, 1, 114–120.
87. Misbach, J.; Andradi, S.; Harahap, T.P.; Soemargo, S.; Markam, S. Double blind trial of Nicholin (CDP-choline) on the patients with severe head injury. In Biannual Meeting of Neurology, Psychiatry and Neurosurgery; Surabaya, Indonesia, 1978.
88. Ayuso, J.L.; Saiz, J. Efecto protector del citidín-5-difosfato de colina sobre el defecto mnésico post-electrochoque. Munch. Med. Wochenschr. 1977, 119, 53–59.
89. De la Herrán, J.; Cortina, C.; Salazar, J.; de Monge, F. Utilización del citidín difosfato de colina en lesiones encefálicas graves. Actas Luso Esp. Neurol. Psiquiatr. Ciencias Afines. 1978, 6, 3–12.
90. Espagno, J.; Trémoulet, M.; Gigaud, M.; Espagno, C. Étude de l’action de la CDP-choline dans les troubles de la vigilance post-traumatique. Vie Médicale 1979, 3, 195–196.
91. Carcasonne, M.; LeTourneau, J.N. Étude en double insu du réxort en neurotraumatologie infantile. Vie Médicale 1979, 12, 1007.
92. Richer, E.; Cohadon, F. Essai thérapeutique d’un précurseur des phospholipides sur le traitement des comas traumatiques. In Symposium International: Souffrance cérébrale et Précurseurs des Phospholipides; Laboratoires Cassenne-Takeda: Paris, France, 1980.
93. Lecuire, J.; Duplay, J. Sperimentazione in doppio cieco della citicolina versus meclofenossato in pazienti colpiti da trauma cranico. G. Ital. Ric. Clin. Ter. 1982, 3, 51–55.
94. Lecuire, J.; Duplay, J. Sperimentazione della citicolina in un camipone di 154 traumatizzati cranici. G. Ital. Ric. Clin. Ter. 1982, 3, 61–67.
95. Lecuire, J. Traumatismes crâniens: Étude comparative piracetam-CDP-choline. C. R. Ther. Pharmacol. Clin. 1985, 3, 3–7.
96. Cohadon, F.; Richer, E.; Poletto, B. Etude d’un precurseur des phospholipides dans le traitement des comas traumatiques graves (A precursor of phospholipids in the treatment of severe traumatic comas). Neurochirurgie 1982, 28, 287–290.
97. Deleuze, R.; Huguenard, P.; Laborit, G.; Roujas, F. Effets de la CDP-choline sur le rapport lactates/pyruvates dans le LCR en cas de souffrance cérébrale grave. C. R. Ther. 1985, 4, 11–18.
98. Ogashiwa, M.; Takeuchi, K.; Hara, M.; Tanaka, Y.; Okada, J. Studies on the intrathecal pharmacotherapy. Part I: CDP-choline. Int. J. Clin. Pharmacol. Biopharm. 1975, 12, 327–335.
99. Ogashiwa, M.; Takeuchi, K. Intrathecal pharmacotherapy in coma. Acta Neurochir. 1976, 34, 37–44.
100. De Blas, A.; Martínez-Cubells, J.; Hernando, C. Valoración de la efectividad de la citicolina en el tratamiento de los traumatismos craneoencefálicos. Med. Clin. 1986, 87 (Suppl. 1), 41–44.
101. Ragguenneau, J.L.; Jarrige, B. Enquête nationale sur les suites des traumatismes crâniens graves: Analyse des 219 traumatismes traités par CDP-choline. Agressologie 1988, 29, 439–443.
102. Calatayud Maldonado, V.; Calatayud Pérez, J.B.; Aso Escario, J. Effects of CDP-choline on the recovery of patients with head injury. J. Neurol. Sci. 1991, 103, S15–S18.
103. Lozano, R. CDP-choline in the treatment of cranio-encephalic traumata. J. Neurol. Sci. 1991, 103, S43–S47.
104. Lazowski, T.; Kierul, K.; Bartnicki, M.; Mayzner-Zawadzka, E.; Toczylowska, B.; Ryba, M.; Lewandowski, Z. Effects of citicoline treatment in patients with isolated head trauma: A randomized trial. Critical Care 2003, 7 (Suppl. 2), 78.
105. Hinev, S.; Tzoneva, D.; Ljubenova, K.; Tzvetkov, V.; Dimitrov, G.; Stefanov, I. Neuroprotection as component of complex therapy in patients with severe head trauma and cerebrovascular diseases. Anaesthesiol. Intensive Care 2007, 34, 19–24.
106. Krishna, D.; Chaurasia, I.D.; Jethwani, U. Role of citicoline in traumatic brain injury: A randomized controlled study. IJPMR 2012, 2, 1–5.
107. Zafonte, R.; Friedewald, W.T.; Lee, S.M.; Levin, B.; Diaz-Arrastia, R.; Ansel, B.; Eisenberg, H.; Timmons, S.D.; Temkin, N.; Novack, T.; et al. The citicoline brain injury treatment (COBRIT) trial: Design and methods. J. Neurotrauma 2009, 26, 2207–2216.
108. Zafonte, R.D.; Bagiella, E.; Ansel, B.M.; Novack, T.A.; Friedewald, W.T.; Hesdorffer, D.C.; Timmons, S.D.; Jallo, J.; Eisenberg, H.; Hart, T.; et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA 2012, 308, 1993–2000.
109. El Reweny, E.M.; Okasha, A.; Hafez, A. The neuroprotective effect of citicholine (CDP choline) in patients with traumatic brain injury. In Proceedings of the 25th ESICM Annual Congress, Lisbon, Portugal, 13–17 October 2012.
110. Varadaraju, D.N.; Ananthakishan, A. Effect of cerebroprotein hydrolysate with citicoline versus citicoline alone in the initial management of head injury and its clinical outcome a prospective randomised comparative study. J. Evid. Based Med. Healthc. 2017, 4, 2835–2837.
111. Titov, I.I.; Voloshinsky, O.V.; Martin, A.Y.; Vintonyak, I.V.; Nestor, I.I. Evaluation of neuroprotectoral therapy efficiency in TBI. Pain Anesth. Intensive Care 2018, 3, 61–68.
112. Trimmel, H.; Majdan, M.; Wodak, A.; Herzer, G.; Csomor, D.; Brazinova, A. Citicoline in severe traumatic brain injury: Indications for improved outcome: A retrospective matched pair analysis from 14 Austrian trauma centers. Wien. Klin. Wochenschr. 2018, 130, 37–44.
113. Ahmadi, J.; Hoseinzadeh-Chahkandak, F.; Roobiyat, M.Y.; Pourbagher-Shahri, A.M.; Irankhah, S.; Rajabpour-Sanati, A. Comparison of two different doses of citicoline in patients with traumatic brain injury. J. Surg. Trauma 2020, 8, 8–15.
114. Salehpour, F.; Shokouhi, G.; Shakeri, M.; Shimia, M.; Mahdkhah, A.; Baradaran, A.; Imani, M.T.; Mirzaee, F.; Azar, A.K.; Bazzazi, A.M.; et al. Neuroprotective effects of citicoline in diffuse axonal injuries. Adv. Biosci. Clin. Med. 2013, 1, 12–15.
115. Salehpour, F.; Aghazade, J.; Mirzaee, F.; Mahdkhah, A. Citicoline in patients with traumatic brain injuries. EC Neurol. 2015, 2, 87–93.
116. Shokouhi, G.; Haghjoo, A.G.; Sattarnezhad, N.; Asghari, M.; Sattarnezhad, A.; Asghari, A.; Pezeshki, A. Effects of citicoline on level of consciousness, serum level of fetuin-A and matrix Gla-protein (MGP) in trauma patients with diffuse axonal injury (DAI) and GCS ≤ 8. Ulus Travma Acil. Cerrahi. Derg. 2014, 20, 410–416.
117. Levin, H.S. Treatment of postconcussional symptoms with CDP-choline. J. Neurol. Sci. 1991, 103, S39–S42.
118. Aniruddha, T.J.; Pillai, S.; Devi, B.I.; Sampath, S.; Chandramouli, B.A. Role of citicoline in the management of mild head injury. Indian J. Neurotrauma 2009, 6, 49–52.
119. Jotwani, V.; Harmon, K.G. Postconcussion syndrome in athletes. Curr. Sports Med. Rep. 2010, 9, 21–26.
120. León-Carrión, J.; Domínguez-Roldán, J.M.; Murillo-Cabeza, F.; Domínguez-Morales, M.R.; Muñoz-Sánchez, M.A.; Forastero, P. Advances in the treatment of memory deficits after brain injury: The role of citicholine. In Proceedings of the 3rd World Congress on Brain Injury, Quebec City, QC, Canada, 12–17 June 1999.
121. León-Carrión, J.; Domínguez-Roldán, J.M.; Murillo-Cabeza, F.; Domínguez-Morales, M.R.; Muñoz-Sánchez, M.A. Normalization of memory-related cerebral blood flow in severe traumatic brain injury patients and improvements of memory induced by citicholine (CDP-choline): The role of a pro-cognitive drug. In Proceedings of the International Conference on Recent Advances in Neurotraumatology, ICRAN’99, Taipei, Taiwan, 20–23 November 1999.
122. León-Carrión, J.; Domínguez-Roldán, J.M.; Murillo-Cabeza, F.; Domínguez-Morales, M.R.; Muñoz-Sánchez, M.A. The role of citicholine in neuropsychological training after traumatic brain injury. Neurorehabilitation 2000, 14, 33–40.
123. Wortzel, H.S.; Arciniegas, D.B. Treatment of post-traumatic cognitive impairments. Curr. Treat. Options Neurol. 2012, 14, 493–508.
124. Spiers, P.A.; Hochanadel, G. Citicoline for traumatic brain injury: Report of two cases, including my own. J. Int. Neuropsychol. Soc. 1999, 5, 260–264.
125. Secades, J.J. Citicoline for the Treatment of Head Injury: A Systematic Review and Meta-analysis of Controlled Clinical Trials. J. Trauma. Treat 2014, 4, 227.
126. El Sayed, I.; Zaki, A.; Fayed, A.M.; Shehata, G.M.; Abdelmonem, S. A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury. Neurosurg. Rev. 2018, 41, 427–438.